Haemonetics Widens FY2027 Sales Guidance from $1.410B-$1.427B to $1.401B-$1.441B vs $1.402B Est

Benzinga Newsdesk www.benzinga.com Positive 71.3%

Neg 0% Neu 0% Pos 71.3%

Haemonetics (NYSE:HAE) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 billion-$1.441 billion vs $1.402 billion estimate.